PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35589772-0	2022	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.	lenvatinib	122-132	C-reactive protein	Homo sapiens	0-18	
33351844-0	2020	C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.	lenvatinib	114-124	C-reactive protein	Homo sapiens	0-18	
33351844-10	2020	CONCLUSIONS: CRP level was associated with OS in HCC patients treated with lenvatinib.	lenvatinib	75-85	C-reactive protein	Homo sapiens	13-16	
33351844-11	2020	CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment.	lenvatinib	78-88	C-reactive protein	Homo sapiens	0-3